{"id":"gemcitabine-cisplatin-and-bevacizumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Neuropathy"},{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Hypertension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Gemcitabine is a nucleoside analog that disrupts DNA synthesis in rapidly dividing cells. Cisplatin is a platinum-based alkylating agent that cross-links DNA and triggers apoptosis. Bevacizumab is a monoclonal antibody targeting VEGF that prevents angiogenesis, starving tumors of blood supply. Together, these agents provide dual chemotherapy with anti-angiogenic support.","oneSentence":"This combination uses gemcitabine and cisplatin as chemotherapy agents to damage cancer cell DNA, while bevacizumab blocks tumor blood vessel formation to inhibit cancer growth.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:47:03.734Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic non-small cell lung cancer"},{"name":"Ovarian cancer"},{"name":"Bladder cancer"}]},"trialDetails":[{"nctId":"NCT05211323","phase":"PHASE2","title":"A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-12-07","conditions":"Combined Hepatocellular Carcinoma and Cholangiocarcinoma, Stage III Liver Cancer, Stage IV Liver Cancer","enrollment":88},{"nctId":"NCT07174947","phase":"PHASE2","title":"SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety","status":"RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-10-01","conditions":"Hepatobiliary Malignancy, Fluoxetine, Anxiety Disorders","enrollment":240},{"nctId":"NCT05281471","phase":"PHASE3","title":"Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)","status":"RECRUITING","sponsor":"Genelux Corporation","startDate":"2022-08-31","conditions":"Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer","enrollment":186},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT07111546","phase":"PHASE2","title":"A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]","status":"RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2025-10-20","conditions":"Advanced Solid Tumour","enrollment":140},{"nctId":"NCT03178552","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-09-22","conditions":"Non-Small Cell Lung Cancer","enrollment":1000},{"nctId":"NCT06447662","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-06-27","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":330},{"nctId":"NCT05775159","phase":"PHASE2","title":"Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-04-24","conditions":"Hepatocellular Carcinoma, Biliary Tract Cancer","enrollment":294},{"nctId":"NCT03498521","phase":"PHASE2","title":"A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-07-10","conditions":"Cancer of Unknown Primary Site","enrollment":529},{"nctId":"NCT07233850","phase":"PHASE2","title":"A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers","status":"NOT_YET_RECRUITING","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","startDate":"2025-11","conditions":"Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)","enrollment":300},{"nctId":"NCT05305131","phase":"PHASE2","title":"Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2022-03-28","conditions":"Nasopharyngeal Cancer","enrollment":50},{"nctId":"NCT07171528","phase":"PHASE2","title":"Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer","status":"RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2025-09-10","conditions":"Ovarian Cancer","enrollment":80},{"nctId":"NCT03929666","phase":"PHASE2","title":"A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2019-08-29","conditions":"HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer","enrollment":74},{"nctId":"NCT05007106","phase":"PHASE2","title":"MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-16","conditions":"Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck","enrollment":613},{"nctId":"NCT03872947","phase":"PHASE1","title":"A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Toray Industries, Inc","startDate":"2019-04-26","conditions":"Solid Tumor, Colorectal Cancer, Cholangiocarcinoma","enrollment":138},{"nctId":"NCT07001618","phase":"PHASE2","title":"Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-09","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer)","enrollment":162},{"nctId":"NCT06292286","phase":"NA","title":"Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2023-11-01","conditions":"Recurrent Ovarian Carcinoma","enrollment":18},{"nctId":"NCT00324805","phase":"PHASE3","title":"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-07-19","conditions":"Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7","enrollment":1501},{"nctId":"NCT03632798","phase":"PHASE3","title":"Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer","status":"WITHDRAWN","sponsor":"Cordgenics, LLC","startDate":"2018-08-01","conditions":"Recurrent Ovarian Cancer","enrollment":""},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":"Metastatic Breast Cancer","enrollment":1460},{"nctId":"NCT04999761","phase":"PHASE1","title":"AB122 Platform Study","status":"RECRUITING","sponsor":"Taiho Pharmaceutical Co., Ltd.","startDate":"2021-06-01","conditions":"Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer","enrollment":917},{"nctId":"NCT06349044","phase":"NA","title":"A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2024-03-20","conditions":"Her-2 Negative Adenocarcinoma of the Gastro-oesophageal Junction/Gastric Adenocarcinoma, Hepatocellular Carcinoma, Biliary Tract Carcinoma","enrollment":120},{"nctId":"NCT05684731","phase":"PHASE1","title":"Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2023-02-01","conditions":"Ovarian Cancer","enrollment":30},{"nctId":"NCT04677504","phase":"PHASE2","title":"A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-02-23","conditions":"Biliary Tract Cancer","enrollment":162},{"nctId":"NCT06364826","phase":"PHASE2","title":"Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2024-04-22","conditions":"Nasopharyngeal Carcinoma","enrollment":60},{"nctId":"NCT00942331","phase":"PHASE3","title":"Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-07-15","conditions":"Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Prostate Carcinoma","enrollment":506},{"nctId":"NCT05757336","phase":"PHASE2","title":"Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer","status":"RECRUITING","sponsor":"Lu Wang, MD, PhD","startDate":"2022-12-22","conditions":"Gallbladder Cancer, Initially Unresectable, the First Line Treatment","enrollment":50},{"nctId":"NCT00312728","phase":"PHASE2","title":"A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2006-03","conditions":"Non-Small Cell Lung Cancer, Brain Neoplasms","enrollment":115},{"nctId":"NCT05341193","phase":"PHASE1, PHASE2","title":"PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-04-30","conditions":"Nasopharyngeal Carcinoma","enrollment":32},{"nctId":"NCT03690739","phase":"PHASE3","title":"Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer","status":"TERMINATED","sponsor":"AGO Research GmbH","startDate":"2019-08-09","conditions":"Recurrent Ovarian Carcinoma","enrollment":9},{"nctId":"NCT01454102","phase":"PHASE1","title":"Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-12-16","conditions":"Non-small Cell Lung Cancer","enrollment":472},{"nctId":"NCT02715531","phase":"PHASE1","title":"A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-04-06","conditions":"Solid Tumor","enrollment":243},{"nctId":"NCT01309633","phase":"PHASE2","title":"Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)","status":"COMPLETED","sponsor":"National University Hospital, Singapore","startDate":"2011-09-02","conditions":"Nasopharyngeal Carcinoma","enrollment":80},{"nctId":"NCT00354549","phase":"PHASE2","title":"Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLC","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"2006-01","conditions":"Lung Cancer","enrollment":104},{"nctId":"NCT03925233","phase":"","title":"Breast Cancer Treatment Based on Organ-like Culture","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2019-01-02","conditions":"Breast Cancer Organoids","enrollment":300},{"nctId":"NCT00924209","phase":"PHASE2","title":"A Phase II Study of Neo-Adjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2) Non-Squamous Cell Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-03","conditions":"NSCLC, Stage IIIA (N2)","enrollment":7},{"nctId":"NCT00268450","phase":"PHASE2","title":"Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery","status":"TERMINATED","sponsor":"Medical University of South Carolina","startDate":"2005-09-21","conditions":"Bladder Cancer","enrollment":21},{"nctId":"NCT01936974","phase":"PHASE2","title":"(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma","status":"TERMINATED","sponsor":"Western Regional Medical Center","startDate":"2013-09","conditions":"Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma","enrollment":7},{"nctId":"NCT01383148","phase":"PHASE2, PHASE3","title":"Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Transgene","startDate":"2012-04","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":222},{"nctId":"NCT00642824","phase":"PHASE2","title":"A Genetic Substudy Associated With the Avastin (Bevacizumab) Study MO19390 in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2007-05","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":3},{"nctId":"NCT00806923","phase":"PHASE3","title":"A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-02","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":1044},{"nctId":"NCT02316327","phase":"PHASE4","title":"Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab","status":"COMPLETED","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2013-07","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":19},{"nctId":"NCT00404703","phase":"PHASE2","title":"A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2006-08","conditions":"Non-Small Cell Lung Cancer","enrollment":37},{"nctId":"NCT00705874","phase":"PHASE1","title":"Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma","status":"COMPLETED","sponsor":"Progen Pharmaceuticals","startDate":"2006-05","conditions":"Cancer","enrollment":172},{"nctId":"NCT02829008","phase":"PHASE2","title":"Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2016-04","conditions":"Metastatic Breast Cancer","enrollment":120},{"nctId":"NCT00234494","phase":"PHASE2","title":"Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer","status":"COMPLETED","sponsor":"Christopher Sweeney, MBBS","startDate":"2005-11","conditions":"Bladder Cancer","enrollment":45},{"nctId":"NCT02701231","phase":"NA","title":"Low-frequency Rotating Magnetic System Combined With Systemic Anti-tumor Therapy for Advanced Lung Cancer","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2015-11","conditions":"Lung Neoplasms","enrollment":200},{"nctId":"NCT01077713","phase":"PHASE2","title":"A Study of Avastin (Bevacizumab) in Combination With Gemcitabine With or Without Cisplatin in First-Line Treatment of Elderly Patients With Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-02","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":86},{"nctId":"NCT00458315","phase":"PHASE2","title":"Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor","status":"WITHDRAWN","sponsor":"Rigshospitalet, Denmark","startDate":"2007-05","conditions":"Unknown Primary Tumors","enrollment":""},{"nctId":"NCT00531960","phase":"PHASE2","title":"A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-01","conditions":"Non-Small Cell Lung Cancer","enrollment":124},{"nctId":"NCT00620971","phase":"PHASE2","title":"Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus the Cisplatin/Docetaxel/Bevacizumab Combination in Locally Advanced or Metastatic NSCLC","status":"COMPLETED","sponsor":"Hellenic Oncology Research Group","startDate":"2008-01","conditions":"Non Small Cell Lung Cancer","enrollment":77},{"nctId":"NCT00027703","phase":"PHASE2","title":"Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-10","conditions":"Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Localized Malignant Mesothelioma","enrollment":106},{"nctId":"NCT00536640","phase":"PHASE2","title":"Inoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study With Bevacizumab Plus Erlotinib Or Gemcitabine/Cisplatin Plus Bevacizumab","status":"COMPLETED","sponsor":"Aktion Bronchialkarzinom e.V.","startDate":"2007-11","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":224},{"nctId":"NCT01623102","phase":"PHASE2","title":"Cisplatin and Gemcitabine With or Without Bevacizumab in EGFR Wild-type Non-Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Sichuan Cancer Hospital and Research Institute","startDate":"2013-02","conditions":"Lung Cancer","enrollment":40},{"nctId":"NCT00126633","phase":"PHASE2","title":"Gemcitabine, Cisplatin, and Bevacizumab in Treating Patients With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2004-04","conditions":"Pancreatic Cancer","enrollment":53}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Avastin"],"phase":"marketed","status":"active","brandName":"gemcitabine, cisplatin and bevacizumab","genericName":"gemcitabine, cisplatin and bevacizumab","companyName":"Fundacion Clinic per a la Recerca Biomédica","companyId":"fundacion-clinic-per-a-la-recerca-biom-dica","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses gemcitabine and cisplatin as chemotherapy agents to damage cancer cell DNA, while bevacizumab blocks tumor blood vessel formation to inhibit cancer growth. Used for Advanced or metastatic non-small cell lung cancer, Ovarian cancer, Bladder cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}